Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in Pregnancies at Risk for Severe HDFN
NCT05912517Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of nipocalimab in hemolytic disease of the fetus and newborn (HDFN), sponsored by Janssen Pharmaceutical. Started Dec 2023; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
hemolytic disease of the fetus and newborn (HDFN)
Beyond the preview
Go deeper on NCT05912517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05912517.